Evaluation on Visual Outcome of TMS

Evaluation on Visual Outcome of Transcranial Magnetic Stimulation

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT06612190

Enrollment

300

Registered

2024-09-25

Start date

2024-09-15

Completion date

2035-10-01

Last updated

2026-09-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Visual Impairment

Brief summary

The goal of this clinical trial is to learn if transcranial magnetic stimulation (TMS) can improve the visual outcomes in patients with visual impairment. The main question it aims to answer is: • Does TMS improve the visual outcome in patients who suffer from visual impairment? Researchers will compare TMS to the control group who will not receive effective TMS treatment) to see if TMS works to improve the visual outcomes of the patients. Participants will * Undergo TMS treatment or no effective TMS for consecutive 5 days. * Visit the clinic once every 2 weeks for checkups and tests.

Interventions

PROCEDURETMS

TMS treatment in this study indicates a non-invasive procedure called transcranial magnetic simulation (TMS) on visual cortex. The treatment intensity is set as 80% of the threshold of each participant. The treatment will be conducted every day for consecutive 5 days.

PROCEDUREControl

The control group will be given conventional consecutive care.

Study design

Allocation

NON_RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

6 Years to 80 Years

Healthy volunteers

Inclusion criteria

* Post cataract surgery or clear lens * Best-corrected visual acuity less than 0.1logMAR

Exclusion criteria

* Diagnosed with cognitive impairment or mental disorders and unable to cooperate with treatment; * Diagnosed with ocular diseases that affect observation of visual function; * History of epileptic seizures; * Long term use of psychotropic drugs； * Metal implants in the body.

Design outcomes

Primary

Measure	Time frame
Visual acuity	From enrollment to the end of treatment at 6 months

Secondary

Measure	Time frame
Visual field	From enrollment to the end of treatment at 6 months